Diabetes potentiates acetylcholine-induced relaxation in rabbit renal arteries

The response of rabbit renal arteries to acetylcholine and its endothelial modulation in diabetes were investigated. Acetylcholine induced concentration-related endothelium-dependent relaxation of renal arteries that was significantly more potent in diabetic rabbits than in control rabbits. Pretreatment with N(G)-nitro-L-arginine (L-NOArg), indomethacin, or L-NOArg plus indomethacin induced partial inhibition of acetylcholine-induced relaxation. Inhibition induced by L-NOArg plus indomethacin was significantly higher in arteries from diabetic rabbits than in arteries from control rabbits. In renal arteries depolarised with KCl 30 mM and incubated with L-NOArg plus indomethacin, acetylcholine-induced relaxation was almost abolished in both groups of rabbits and this response was not different from that obtained in arteries without endothelium. Sodium nitroprusside induced concentration-dependent relaxation of renal arteries from control and diabetic rabbits without significant differences between the two groups of animals. These results suggest that diabetes potentiates the acetylcholine-induced relaxation in rabbit renal arteries. Increased release of nitric oxide and prostacyclin could be responsible for the enhanced relaxant potency of acetylcholine in diabetes.     

Neuropeptide Y inhibits relaxation of guinea pig cerebral, coronary, and uterine arteries: blockade by D-myo-inositol-1,2,6-triphosphate.

Interactions between neuropeptide Y and perivascular vasodilator agents were studied in guinea pig cerebral, coronary, and uterine arteries. In all three types of arteries, vessel segments precontracted with prostaglandin F2 alpha or histamine relaxed concentration dependently upon application of acetylcholine (ACh), substance P (SP), and vasoactive intestinal peptide (VIP). Neuropeptide Y (NPY: 10(-8)-10(-7) M) caused inhibition of relaxations produced by ACh, SP, and VIP in all three types of segments; however, the effective concentration varied between vessel type. Thus, cerebral and uterine arteries were approximately 10 times more sensitive to NPY than the coronary artery. D-myo-inositol-1,2,6-triphosphate (PP56) was a potent inhibitor of the NPY effect in all three vessel types. Thus, NPY, which is colocalized not only with norepinephrine in sympathetic perivascular fibers but also with VIP and ACh in some parasympathetic neurons, can greatly reduce the vasodilatory effect of ACh and VIP, as well as of the sensory peptide SP. This further illustrates the complex interactions NPY has with perivascular neuroeffector mechanisms.     

Effects of neuropeptide Y on contraction, relaxation, and membrane potential of rabbit cerebral arteries

The effects of porcine neuropeptide Y (NPY) on agonist-induced contraction, relaxation, and intracellular membrane potential were studied in isolated ring segments of rabbit cerebral arteries. NPY caused contraction of cerebral arteries with a mean EC50 of 2.7 +/- 0.07 nM. After exposure of cerebral arteries to 1.5 nM NPY, the potencies of norepinephrine (NE) and histamine in causing contraction were increased by approximately twofold, with no change in maximal contraction. In cerebral arteries contracted with histamine, adenosine, and acetylcholine-induced relaxation was inhibited by 7-14-fold in the presence of 1.5 nM NPY, with no change in maximal relaxation. These effects of NPY were not altered by sympathetic denervation of cerebral arteries. Intracellular membrane potential in smooth muscle cells of cerebral arteries was measured using glass microelectrodes and averaged -66 +/- 1 mV. NPY 3 nM, ouabain 3 microM, and K+ Krebs solution 1 mM depolarized cerebral arteries by 15, 22, and 14 mV, respectively. In arteries depolarized by ouabain or 1 mM K+ Krebs solution, 3 nM NPY caused no additional depolarization. The potency of NE in causing contraction of cerebral arteries was increased by 3 microM ouabain (3.8-fold) and 1 mM K+ Krebs solution (1.9-fold); however, 3 nM NPY in the presence of ouabain or 1 mM K+ Krebs solution caused no greater increase in agonist potency. Ouabain 3 microM inhibited adenosine-induced relaxation by 5.1-fold whereas addition of 3 nM NPY to ouabain exposed arteries caused an additional 4.6-fold inhibition of relaxation. Ouabain and ouabain plus NPY also decreased the maximal relaxant effect of adenosine. These results suggest that the ability of NPY to potentiate contraction and inhibit relaxation of cerebral arteries is caused, at least in part, by NPY-induced membrane depolarization.     

Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels.

The contractile effect of neuropeptide Y (NPY) was tested on isolated segments of basilar artery, central ear artery, gastro-epiploic artery and vein, and femoral artery and vein from the rabbit. At 30 nM NPY did not evoke vasoconstriction; at 300 nM NPY evoked a weak and variable response. NPY greatly potentiated the response of the gastro-epiploic and femoral arteries to noradrenaline without affecting the maximum response. As tested on the gastro-epiploic artery NPY was effective at concentrations of 1 nM and higher. As tested on the femoral artery the potentiating effect of 30 nM NPY on noradrenaline-evoked contractions was apparent immediately and 30 min after the application of NPY, but not after one hour. NPY (30 nM) potentiated the contractile response to noradrenaline and histamine but not to 5-hydroxytryptamine or high K+. The response to histamine was augmented in both arteries and veins, whereas the response to noradrenaline was enhanced in arteries but not in veins. NPY failed to potentiate the prostaglandin F2 alpha-evoked contraction except in the gastro-epiploic vein.     

Elevation of cyclic AMP by prostacyclin is accompanied by relaxation of bovine coronary arteries and contraction of rabbit aortic rings

The role of cyclic AMP (cAMP) in the control of vascular smooth muscle tension was examined by comparing the effects of prostacyclin (PGI2) on tension and cAMP levels in helical strips of bovine coronary arteries and in rabbit aortic rings, both denuded of endothelium. In bovine coronary arteries, PGI2 elevated cAMP levels and relaxed the muscles. The PGI2-induced cAMP elevation preceded the relaxation and both parameters were altered in a dose-dependent manner by increasing concentrations of PGI2 (0.3, 3 and 30 microM). These results are consistent with a role for cAMP as a mediator of vascular smooth muscle relaxation. Cyclic AMP levels were also elevated by PGI2 in a concentration- and time-dependent manner in rabbit aortic rings. However, in direct contrast to the results in the bovine coronary arteries, PGI2-induced elevation of cAMP in the aortic rings was accompanied by contraction rather than relaxation. Isoproterenol, a drug which is generally believed to relax smooth muscles by virtue of its ability to increase tissue levels of cAMP, relaxed PGI2-contracted aortic rings with no further elevation of cAMP beyond that caused by the PGI2 alone. These results demonstrate that cAMP elevation and relaxation of vascular smooth muscle are not always well correlated. It is possible that some form of functional compartmentalization of cAMP or cAMP-dependent protein kinase exists in these tissues.     

Nisoldipine-induced relaxation in intact and skinned smooth muscles of rabbit coronary arteries

In smooth muscles of the rabbit coronary artery, nisoldipine inhibited the phasic and tonic responses of the contraction induced by 128 mM K (the IC50 values were 4 X 10(-8) M and 1 X 10(-13) M, respectively). This agent also inhibited the tonic response of the acetylcholine (ACh) (10(-5) M)-induced contraction (the IC50 value was 3 X 10(-10) M), but only slightly inhibited the phasic response (in 10(-7) M, 0.86 times the control). Nisoldipine (less than 10(-7) M) had no effect on the K-induced depolarization of the membrane at any given concentration. This drug (5 X 10(-8) M) did inhibit the oscillatory potential changes and spike potential evoked on the ACh-induced slow depolarization. After depletion of stored Ca from the polarized muscles (5.9 mM K), muscle cells accumulated Ca by application of 2.6 mM Ca without generation of contraction, i.e. a subsequently applied 20 mM caffeine produced the contraction in Ca-free solution. Nisoldipine (less than 10(-7) M) had little effect on this accumulation of Ca. The rate of rise and time to reach the maximum amplitude of the 128 mM K- or ACh-induced contraction (in 2.6 mM Ca) depended on the amount of stored Ca in cells. Nisoldipine (10(-8) M) consistently inhibited the Ca-induced contraction evoked in depolarized muscles (128 mM K), regardless of the amount of stored Ca. However, this agent (10(-8) M) did not inhibit the Ca release from storage sites evoked by activation of the muscarinic receptor. After prolonged superfusion (over 120 min) with Na- and Ca-free solution (guanethidine and atropine were present), application of 2.6 mM Ca produced contraction which was inhibited by 10(-8) M nisoldipine, while the depolarization induced by application of these solutions was not inhibited by nisoldipine. In saponin-skinned muscles, nisoldipine had no effect on the contractile proteins, as estimated from the pCa-tension relationship, or on the Ca accumulation into the Ca release from the Ca storage sites, as estimated from the caffeine-induced contraction. It is concluded that nisoldipine possesses a selective inhibitory action on voltage-dependent Ca influx, when the Ca channel is activated by depolarization.     

Adenosine diphosphate potentiates the inhibition of norepinephrine-induced relaxation by 5-hydroxytryptamine in canine coronary arteries

Vasoactive substances released from aggregating platelets inhibit beta-adrenergic neurotransmission in coronary arteries. Studies were carried out on the effects of two such vasoactive substances on canine coronary arteries, at concentrations equivalent to that released by platelets under physiological conditions. 5-Hydroxytryptamine (5 X 10(-7) M) reduced the sensitivity of coronary artery ring segments to the beta-adrenergic relaxing effects of norepinephrine. Adenosine diphosphate (3 X 10(-6) M) further reduced the sensitivity to norepinephrine caused by 5-hydroxytryptamine, while the nucleotide alone had no significant effect. 5-Hydroxytryptamine and adenosine diphosphate acted selectively on the norepinephrine-induced relaxation; whereas the relaxatory response of the vessel to nitroprusside, a direct muscle relaxant, was unaffected. 5-Hydroxytryptamine caused contraction of the tissue, but this opposing response did not account for the inhibition of the norepinephrine-induced relaxation observed in the presence of the indoleamine. The decreases in sensitivity to norepinephrine caused by 5-hydroxytryptamine and adenosine diphosphate were prevented by the serotonin receptor antagonist, methiothepin. The potentiation by adenosine diphosphate of the 5-hydroxytryptamine-induced shift in the relaxation caused by norepinephrine was blocked by the purine receptor antagonist, 8-(p-sulfophenyl)-theophylline. Neither adenosine nor alpha,beta-methylene adenosine diphosphate potentiated the action of 5-hydroxytryptamine, suggesting that phosphate hydrolysis of the nucleotide is required for the action of adenosine diphosphate. These results suggest that adenosine diphosphate potentiates the inhibitory effect of 5-hydroxytryptamine on the beta-adrenergic response of coronary arteries exposed to vasoactive substances released from platelets.     

Tetrandrine potentiates caffeine-induced contraction but inhibits phenylephrine-induced contraction in perfused rat mesenteric artery

Effects of tetrandrine (TET), a bisbenzylisoquinoline alkaloid, on the contractile responses of perfused rat mesenteric arteries to phenylephrine (PE) and caffeine were investigated. TET concentration-dependently (1-30 micro M) attenuated phenylephrine-induced responses but potentiated the contractile responses to caffeine (5-40 mM) in the presence and absence of Ca(2+). Berbamine (BER), a structural analogue of TET, elicited a relatively smaller inhibitory effect on the responses to PE due to Ca(2+) release or Ca(2+) influx. However, both TET and BER elicited a comparable potentiating effect on caffeine-induced contraction. Cyclopiazonic acid (CPA; 10 micro M), a selective sarcoplasmic reticulum Ca(2+)-ATPase pump inhibitor, mimicked the potentiating effect of TET when added 5 min prior to caffeine in Ca(2+)-free medium. However, CPA did not augment and might even inhibit the caffeine-induced response when it was preincubated with the tissue for 25 min prior to the addition of caffeine. We propose that TET elicits differential effects on PE- and caffeine-induced responses in perfused rat mesenteric arterial bed. The inhibitory effect of TET on PE-induced responses is probably due to its direct interactions with alpha-adrenoceptors and PE-sensitive Ca(2+)-channels. The augmentation of caffeine-induced responses by TET, particularly in Ca(2+)-free medium, is likely to be due to its partial inhibition of the sarcoplasmic reticulum Ca(2+)-ATPase pump.     

Selective potentiation of extracellular Ca2+-dependent contraction by neuropeptide Y in rabbit mesenteric arteries

1. Neuropeptide Y (NPY) potentiated the contractile responses induced by electrical transmural stimulation, noradrenaline and KCl in the rabbit mesenteric artery. 2. In preparations treated with noradrenaline or KCl in Ca2+ free medium, NPY also potentiated the contractile response induced by resupplementation of Ca2+. 3. 3H-efflux from the arteries preincubated with [3H]-noradrenaline was not affected by NPY. 4. These results suggest that NPY selectively acts on the postsynaptic membrane and potentiates the contractions mediated through receptor-operated and voltage-dependent Ca channels.     

Neuropeptide Y inhibits double peaked vasoconstrictor responses to periarterial nerve stimulation primarily through prejunctional Y2 receptor subtype in canine splenic arteries

1 The effects of BIIE 0246, a novel and non-peptide neuropeptide Y (NPY) Y2 receptor antagonist on sympathetic vasoconstriction of the canine splenic artery were investigated. 2 The vasoconstrictor response to periarterial electrical nerve stimulation was described to be a double peaked vasoconstriction consisting of an initial transient, dominantly P2X purinoceptor-mediated constriction followed by a prolonged, mainly alpha1 adrenoceptor-induced response. 3 BIIE 0246 at a concentration of 0.1-1 microM dose-dependently potentiated double peaked constrictions at low frequencies (1 and 4 Hz), whereas at high frequency (10 Hz), it failed to affect these responses. BIIE 0246 (1 microM) also enhanced double peaked responses even in the presence of rauwolscine (0.1 microM). NPY (13-36) (1-100 nM), a selective Y2 receptor agonist reduced these two peaked responses in a dose-related manner. The vasoconstriction to noradrenaline (0.1-10 nmol) or adenosine triphosphate (0.01-1 micromol) was not significantly influenced by either 1 microM BIIE 0246 or 100 nM NPY (13-36). Exposure of tissues to 1 microM BIIE 0246 almost completely prevented the suppression of double peaked constrictions by NPY (13-36) (10 nM) or by NPY (10 nM). 4 We conclude that NPY inhibits sympathetic purinergic and adrenergic vasoconstrictions through an activation of prejunctional Y2 receptor subtype in the neurovascular junction of the canine splenic artery.     

Neuropeptide Y (NPY) inhibits spontaneous contraction of the mouse atrium by possible activation of the NPY1 receptor

相似文献   

Inhibition of hypoxia-induced relaxation of rabbit isolated coronary arteries by NG-monomethyl-L-arginine but not glibenclamide.

1. This study describes the in vitro interaction of the muscarinic ligand McNeil-A-343 with two 5-hydroxytryptamine (5-HT) receptor subtypes, the 5-HT4 and 5-HT3 receptors, using functional as well as radioligand binding studies. 2. In the rat oesophageal muscularis mucosae, precontracted with carbachol, McNeil-A-343 was a competitive antagonist (pA2 6.2) of the 5-HT4 receptor which mediates the relaxation induced by 5-HT. The compound per se relaxed the oesophagus at high concentration only (> or = 10 microM), an effect unchanged by desensitization of the 5-HT4 receptor with 10 microM 5-methoxytryptamine. In the same preparation in the absence of tone, McNeil-A-343 displaced the carbachol concentration-response curve to the right, yielding an apparent affinity (pA2) of 4.9 for muscarinic receptors. 3. In the rat isolated superior cervical ganglion preparation, after blockade of muscarinic and nicotinic receptors, McNeil-A-343 caused a concentration-dependent depolarization that was unaffected by 100 nM ondansetron. The concentration-fast depolarization curve to 5-HT, mediated by the 5-HT3 receptor, was displaced to the right by McNeil-A-343, which showed an apparent affinity (pA2) of 4.8 for the 5-HT3 subtype. 4. In binding studies, McNeil-A-343 recognized a single population of 5-HT4 receptors in pig caudate nucleus, with a pKI of 5.9. The binding affinity of McNeil-A-343 for 5-HT3 receptors in NG 108-15 cells was approximately four times lower (pKI 5.3). Binding affinities (pKI) for muscarinic receptor subtypes in rat tissues were 5.3 (M1, cortex), 5.2 (M2, heart) and 4.9 (M3, submandibular glands), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)     

Endothelium-dependent relaxation followed by contraction mediated by NK(1) receptors in precontracted rabbit intrapulmonary arteries

In the present study, we examined whether substance P (SP) and SP methyl ester (SPME), a selective NK(1) agonist, cause biphasic responses consisting of endothelium-dependent relaxation (EDR) and contraction (EDC) in precontracted rabbit intrapulmonary arteries. In arteries contracted with PGF(2alpha) (2x10(-6) M), SP as well as SPME caused only EDR at low concentration (10(-9) M) and EDR followed by EDC at higher concentrations, indicating the involvement of NK(1) receptors. The SP (10(-8) M)-induced EDR was abolished in arteries moderately contracted by PGF(2alpha) (5x10(-7) M) and the EDC in arteries maximally contracted by PGF(2alpha) (10(-5) M), indicating that EDR and EDC are inversely dependent on preexisting tone. Indomethacin (10(-8) - 10(-6) M), a cyclo-oxygenase inhibitor, and ozagrel (10(-8) - 10(-6) M), a TXA(2) synthetase inhibitor attenuated the EDC in the SPME (10(-7) M)-induced biphasic response and markedly potentiated the EDR. AA-861 (10(-8) - 10(-6) M), a 5-lipoxygenase inhibitor, did not affect the EDR or EDC. L-N(G)-nitro-arginine methyl ester (10(-5) - 10(-4) M), a nitric oxide synthase inhibitor, attenuated the EDR and slightly potentiated the EDC. CP-99994 (10(-10) - 10(-8) M), an NK(1) antagonist, attenuated the EDC and potentiated the EDR in the SPME (10(-7) M)-induced biphasic response, while the NK(2) antagonist SR-48968 (10(-9) - 10(-7) M) had no effect. CP-99994 attenuated the SPME (10(-7) M)-induced EDC under EDR-blockade to a greater extent than the EDR under EDC-blockade, indicating that CP-99994 enhanced the EDR component by preferential inhibition of the EDC component. In conclusion, NK(1) agonists caused a biphasic endothelium-dependent response (EDR and EDC) in submaximally precontracted intrapulmonary arteries. The EDC and EDR mediated by NK(1) receptors may play physiological and/or pathophysiological roles in modulation of vascular tone.     

Neuropeptide Y inhibits forskolin-stimulated adenylate cyclase activity in rat hippocampus

Neuropeptide Y inhibited the forskolin-stimulated adenylate cyclase activity in rat hippocampus with the half-maximal effect occurring at 73 nM. The maximal inhibition corresponded to a 17-22% decrease of the control level of enzyme activity. The effect of neuropeptide Y was mimicked by the peptide YY but not by the avian pancreatic polypeptide and required micromolar concentrations of GTP. These results indicate that, in the brain, the inhibition of adenylate cyclase activity constitutes a mechanism by which the receptor for neuropeptide Y transduces its signal.     

Neuropeptide Y potentiates via Y2-receptors the inhibitory effect of noradrenaline in rat locus coeruleus neurones

Summary Intracellular recordings were carried out in a pontine slice preparation of the rat brain containing the locus coeruleus (LC). Pressure application of noradrenaline with various pulse durations inhibited the spontaneous frequency of action potentials and hyperpolarized the membrane. Neuropeptide Y (NPY), its C-terminal fragment NPY(16–36) and peptide YY (PYY), at a concentration of 0.1 µmol/l all, potentiated the effect of noradrenaline, while [Leu³¹, Pro³⁴]NPY (0.1 µmol/l) was inactive. These results are compatible with the presence of Y₂-type NPY-receptors at the cell somata of LC neurones. Correspondence to: P. Illes at the above address     

Neuropeptide Y inhibits depolarization-stimulated catecholamine synthesis in rat pheochromocytoma cells

In PC12 rat pheochromocytoma cells differentiated with nerve growth factor (NGF), neuropeptide Y inhibited depolarization-stimulated catecholamine synthesis as determined by in situ measurement of 3,4-dihydroxyphenylalanine (DOPA) production in the presence of the decarboxylase inhibitor m-hydroxybenzylhydrazine (NSD-1015). The inhibition by neuropeptide Y was concentration-dependent and was prevented by pretreatment with pertussis toxin, suggesting the involvement of a GTP-binding protein of the G_i or G_o subtype. The neuropeptide Y analog[Leu³¹,Pro³⁴]neuropeptide Y also caused inhibition of DOPA production, but was less potent than neuropeptide Y itself, while peptide YY and neuropeptide Y-(13–36) had no significant effect. This pattern is most consistent with the involvement of the neuropeptide Y Y₃ receptor subtype. In PC12 cells differentiated with dexamethasone, neuropeptide Y also caused a concentration-dependent inhibition of DOPA production, while peptide YY was again without effect. Neuropeptide Y had no effect on DOPA production in undifferentiated PC12 cells. These results indicate that neuropeptide Y can modulate catecholamine synthesis in addition to its modulatory effects on catecholamine release.     

Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries

1 We have evaluated the participation of endothelium-derived hyperpolarizing factor (EDHF) in the endothelium-dependent relaxation of isolated human penile resistance arteries (HPRA) and human corpus cavernosum (HCC) strips. In addition, the effect of the angioprotective agent, calcium dobesilate (DOBE), on the endothelium-dependent relaxation of these tissues was investigated. 2 Combined inhibition of nitric oxide synthase (NOS) and cyclooxygenase (COX) nearly abolished the endothelium-dependent relaxation to acetylcholine (ACh) in HCC, while 60% relaxation of HPRA was observed under these conditions. Endothelium-dependent relaxation of HPRA resistant to NOS and COX inhibition was prevented by raising the extracellular concentration of K(+) (35 mM) or by blocking Ca(2)(+)-activated K(+) channels, with apamin (APA; 100 nM) and charybdotoxin (CTX; 100 nM), suggesting the involvement of EDHF in these responses. 3 Endothelium-dependent relaxation to ACh was markedly enhanced by DOBE (10 micro M) in HPRA but not in HCC. The potentiating effects of DOBE on ACh-induced responses in HPRA, remained after NOS and COX inhibition, were reduced by inhibition of cytochrome P450 oxygenase with miconazole (0.3 mM) and were abolished by high K(+) or a combination of APA and CTX. 4 In vivo, DOBE (10 mg kg(-1) i.v.) significantly potentiated the erectile responses to cavernosal nerve stimulation in male rats. 5 EDHF plays an important role in the endothelium-dependent relaxation of HPRA but not in HCC. DOBE significantly improves endothelium-dependent relaxation of HPRA mediated by EDHF and potentiates erectile responses in vivo. Thus, EDHF becomes a new therapeutic target for the treatment of erectile dysfunction (ED) and DOBE could be considered a candidate for oral therapy for ED.